WOCKPHARMA · NSE
Wockhardt Limited
₹2,086.1
+0.67% (+₹13.8)
Prev. close
₹2,072.3
Volume
5,57,349
Delivery %
34.2%
As of
18 Sept 2026
Price history
Vaishali Parekh · Prabhudas Lilladher · 24 Aug 2026
“Bullish on Wockhardt, recommending a buy at ₹1886 with a target of ₹1970 and a stop loss at ₹1850 for intraday traders.”
Entry ₹1,886Target ₹1,970 (+4.5%)Stop ₹1,850 (-1.9%)R:R 2.3:1Target hit · 27 Aug 2026
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Wockhardt, which has seen a breakout from a triangular pattern on the weekly timeframe and is trading above a…” | Article Analysis AnalysisArticle Analysis | Wockhardt Ltd | PENDING | ||||
| “Recommends buying Wockhardt at ₹1904 with a target of ₹2000 and a stop loss of ₹1880 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Wockhardt Ltd | PENDING | ||||
| “Bullish on Wockhardt, recommending a buy at ₹1886 with a target of ₹1970 and a stop loss at ₹1850 for intraday traders.” | Vaishali ParekhPrabhudas Lilladher | Wockhardt | PENDING | ||||
“Bullish on Wockhardt, recommending a buy at ₹1886 with a target of ₹1970 and a stop loss at ₹1850 for intraday traders.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
Fundamentals
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine, as well as offers insulin aspart regular and biphasic drug products. Further, the company offers delivery devices for insulin, including DispoPen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Habil Fakhruddin Khorakiwala
Headquarters
Mumbai
Employees
2,564
Website
wockhardt.comExchange
View on NSE ↗Key stats
Market cap
₹33,897.49 Cr
P/E ratio (TTM)
82.5
EPS (TTM)
₹25.28
Beta (1Y · daily vs NIFTY 50)
0.97
Beta (5Y · monthly vs NIFTY 50)
1.60
Shares float
7.66 Cr
EPS · quarter ended Jun 2026
₹6.55
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.2% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,708.30 Cr | ₹3,230.00 Cr | ₹2,651.00 Cr | ₹2,798.00 Cr | ₹3,012.00 Cr | ₹3,373.00 Cr | |
| EBITDA | ₹-73.24 Cr | ₹135.00 Cr | ₹-81.00 Cr | ₹94.00 Cr | ₹455.00 Cr | ₹678.00 Cr |
| ₹686.06 Cr | ₹-244.00 Cr | ₹-559.00 Cr | ₹-463.00 Cr | ₹-47.00 Cr | ₹213.00 Cr | |
| Diluted EPS | ₹61.56 | ₹-20.24 | ₹-38.79 | ₹-32.05 | ₹-3.02 | ₹13.1 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹7,683.00 Cr | ₹7,649.00 Cr | ₹8,135.00 Cr | ₹8,615.00 Cr | |
| — | — | ₹2,184.00 Cr | ₹2,356.00 Cr | ₹2,021.00 Cr | ₹2,233.00 Cr | |
| Stockholders' equity | — | — | ₹3,354.00 Cr | ₹3,359.00 Cr | ₹4,353.00 Cr | ₹4,940.00 Cr |
Total assets, Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-287.32 Cr | ₹413.00 Cr | ₹153.00 Cr | ₹219.00 Cr | ₹-22.00 Cr | ₹390.00 Cr | |
| Investing cash flow | ₹1,470.10 Cr | ₹-201.00 Cr | ₹-125.00 Cr | ₹-137.00 Cr | ₹-783.00 Cr | ₹-241.00 Cr |
| ₹-1,170.82 Cr | ₹-71.00 Cr | ₹-315.00 Cr | ₹334.00 Cr | ₹409.00 Cr | ₹-54.00 Cr | |
| Capital expenditure | ₹-165.73 Cr | ₹-212.00 Cr | ₹-209.00 Cr | ₹-216.00 Cr | ₹-365.00 Cr | ₹-364.00 Cr |
| End cash position | ₹232.25 Cr | ₹370.00 Cr | ₹90.00 Cr | ₹505.00 Cr | ₹112.00 Cr | ₹217.00 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(3Q) | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24–Mar 24(2Q) | Jun 24–Sep 24(2Q) | Nov 24–Jun 25(4Q) | Sep 25–Jun 26(4Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.04% | 67.13% | 65.75% | 63.83% | 60.36% | 59.31% | 58.40% | 55.14% | 54.93% | 51.60% | 51.99% | 49.09% | 49.08% |
| Public | 31.96% | 32.87% | 34.25% | 36.17% | 39.64% | 40.69% | 41.60% | 44.86% | 45.07% | 48.40% | 48.01% | 50.91% | 50.92% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Wockhardt Limited | ₹33,673.26 Cr | ₹2,086.1 | 82.0 | 6.82 | 4.3% | 0.45 | +13.8% | +36.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
26 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Pharma sector stocks today, September 17: Panacea Biotech gains 2.27%, Alembic Pharma up 2.13%, Wockhardt rises 2%
Wockhardt Limited's stock rose 2.01% to ₹2,062 during early trading on September 17. This increase contributed to an overall positive trend in the pharma sector, with the healthcare index trading 0.60% higher. Several other pharma stocks also saw gains, though some large counters faced pressure.